Innovation Pharmaceuticals Signs Second MTA to Explore Brilacidin as Coronavirus COVID-19 Treatment

    NEXT STORY
    The global nephrology devices market accounted for $12,012 XX million in 2018, and is expected to reach $16,421 XX million by 2026, registering a CAGR of XX4.0% from 2019 to 2026
    PREV STORY
    Cerecor Announces Appointment of H. Jeffery Wilkins MD as Chief Development Officer
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    GUERBET : GEAR 2023 strategic plan

    author_avatar
    NASDAQ Market News

    VBI Vaccines Announces Second Quarter 2018 Financial Results and Provides Corporate Update

    -- Pivotal Phase 3 program for Sci-B-Vac® Hepatitis B vaccine continues to advance towards ...

    author_avatar
    NASDAQ Market News

    Shire Reports Regulatory Milestones for Investigational Hereditary Angioedema (HAE) Treatment Lanadelumab

      Shire Reports Regulatory Milestones for Investigational Hereditary Angioedema (HAE) Treatment Lanadelumab The European Medicines ...

    author_avatar
    NASDAQ Market News